Stephan Ortiz

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study

Austin Kulasekararaj, Anita Hill, Scott T. Rottinghaus et al. · Blood · 2018 · 378 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky, Régis Peffault de Latour, Scott T. Rottinghaus et al. · Haematologica · 2020 · 125 citations · Full text

Medicine, Hematology, Pharmacotherapy +10

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Gema Ariceta, Bradley P. Dixon, Seong Heon Kim et al. · Kidney International · 2020 · 90 citations · Full text

Medicine, Hematology, Pharmacology +15

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Kazuki Tanaka, Brigitte Adams, Álvaro Madrid Arís et al. · Pediatric Nephrology · 2020 · 74 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +11